In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor
about
Reversal of oral anticoagulationThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanNew Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismSafety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirinEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationAnticoagulants and the propagation phase of thrombin generationThe Reversal of Direct Oral Anticoagulants in Animal Models.Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Latest medical treatment strategies for venous thromboembolism.Trends in the development of oral anticoagulants.Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.Oral anticoagulants in pediatric cardiac practice: A systematic review of the literature.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.Anticoagulation by factor Xa inhibitors.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Reversal of novel oral anticoagulants in patients with major bleeding.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNovel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.Pharmacodynamic and pharmacokinetic basics of rivaroxaban.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in JapanA Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study.Stroke Prevention in Atrial Fibrillation: Where are We Now?Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.Rivaroxaban in atrial fibrillation.
P2860
Q26827835-95A5CF4A-61CA-44E7-B0B1-4A282561BA8FQ26828439-C4BC5AD3-7803-4788-B18F-DADE76F47FEBQ26864411-36AD35CB-1D1A-4B19-90D9-7541BA7E382DQ28081366-B2CBA35F-88A8-41EF-9453-1985A5AF0C5EQ28081918-2FA2EAE6-6218-4CDC-B600-8D1DB4BB3D20Q28087447-57892D8D-4765-49AB-86CD-908857D700A1Q28200198-29112B79-3E9C-46FE-AA52-DEA45EAD3EC3Q28477868-9622EF9C-B9FD-452D-8061-74F6F71E6A6BQ28742536-BF0CF66C-EEE6-4278-BD43-FBD0449BEC05Q30491580-43BB3F1C-1A2C-4B35-B7D8-CB4890950993Q30595943-F15CD425-9AE1-416C-B304-71B432CA390DQ33375535-90065712-00AA-4C8D-89FE-16875952C984Q33424198-9724DFB4-78BD-4854-8836-DC3FD38023C2Q34017336-182D6FB0-25BE-4458-9CA8-4371170BDEF4Q34060759-775B31EA-3851-429A-9B9A-F33D32ED63C7Q34065309-FF300BDE-CA4E-4E49-9BC6-12F9B730A466Q34099930-2D48919A-DC3D-4C17-8D9F-B83EE4C81ABFQ34101751-8DDC4E49-68A3-473C-8BC9-03586FF4CEF8Q34130097-A4B58009-2D9B-4B4F-B362-5762B5FF5976Q34206252-E891FDEB-0DB2-4DE9-9DBE-D5E8B1291805Q34252907-89F9FC2F-A513-4B7B-BFE6-4268500882DBQ34326655-DCCFAE0E-9FEF-42C2-8901-1D667EEDB351Q34330708-F14F4239-DFC3-467A-9355-AC1A08A81FF5Q34549913-3295EC52-F5DB-4BBF-ABC5-9E658E06114EQ34561970-449CBFE3-4731-4AE3-9422-22FDCE0D62E1Q34564159-6C978AF9-68D1-4BEE-8117-D3D5B0E616ACQ34627780-B46F5BC9-9D57-4549-AB0E-68889DE34823Q34631714-D0101DB5-539D-4903-AD8C-349D92D147C6Q34635335-BD761538-D52C-47F7-81FE-1E415BAFAD41Q34635548-41651F1B-38BE-427C-99E4-A13E7A6D0813Q34642367-892610C6-1145-42AC-8FDF-E7EABA70A1A6Q34766309-153AF6FE-AB4E-48A4-B867-782C1DDB83CDQ34906214-300C6E0C-783F-4DA1-871B-1E42A9D607EEQ34981567-F277B75E-30BB-4C8C-97FE-E48B4AE2B041Q35099133-06816C12-35E4-4CC9-B8F0-B9F4CC839E67Q35239708-900338F1-1142-4A3C-8D1A-7E8F8215498BQ35505161-75B725B3-7D12-4589-977C-64A6FDC21012Q35811581-7DB06824-CBE5-4032-9A2C-517CE88F98A1Q36138765-9A8F86D2-1D13-4B14-98A3-5A5D577ACE8FQ36207101-EC614C3C-BD78-45B1-8E28-4BCB2280F092
P2860
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@ast
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@en
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@nl
type
label
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@ast
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@en
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@nl
prefLabel
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@ast
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@en
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@nl
P2093
P2860
P3181
P1476
In vitro and in vivo studies o ...... al, direct Factor Xa inhibitor
@en
P2093
E Perzborn
J Pohlmann
J Strassburger
K-H Schlemmer
P2860
P304
P3181
P356
10.1111/J.1538-7836.2005.01166.X
P407
P577
2005-03-01T00:00:00Z